Fast Market Research

New Market Research Report Forecasts the Global Duchenne Muscular Dystrophy Drugs Market to Grow over 150% Annually

Fast Market Research announces the availability of the new TechNavio report, "Global Duchenne Muscular Dystrophy Drugs Market 2015-2019", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 09/08/2015 -- Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death. The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

Get More Details on this Report and a Full Table of Contents at Global Duchenne Muscular Dystrophy Drugs Market 2015-2019

Technavio's analysts forecast the global Duchenne muscular dystrophy drugs market to grow at a CAGR of 152.3% over the period 2014-2019.

Commenting on the report, an analyst from Technavio's team said: "Vendors are focusing on developing drugs that work on novel molecular targets to treat Duchenne muscular dystrophy. For instance, vendors are developing drug candidates based on premature stop codon read-through mechanism such as exon skipping products that target exons such as exon 51, exon 53, exon 45, exon 50, and exon 44, and also PDE5 inhibitors. Gene therapy is also being tested to treat this condition. For instance, Asklepios BioPharmaceutical's pipeline candidate Biostrophin is a gene therapy in the Phase I trials; drisapersen by BioMarin Pharmaceutical and eteplirsen by Sarepta Therapeutics are exon-skipping products; and NPC-14 by Nobelpharma and PTC Therapeutics' ataluren (Translarna) are premature stop codon read-through products. These drugs are expected to have a better safety and efficacy parameter over corticosteroids, which are used as off-label drugs, because they target the underlying cause of the disease and are expected to produce better outcomes in terms of improving the patient's condition."

According to the report, duchenne muscular dystrophy has no known cure. There is only one approved pharmacotherapy to treat this condition. However, many off-label drugs are available in the market such as corticosteroids but these have safety and efficacy issues. There is only one marketed product in the EU, ataluren, which can be used for the treatment of the disorder. However, this drug has not received an approval in the US or rest of the world. In addition, the disease is associated with high treatment and management costs. This provides an opportunity for vendors to invest in R&D to come up with an affordable cure.

Further, the report states that the cost of the treatment of a patient with Duchenne muscular dystrophy is high, making it difficult for many patients to afford the treatment.

The key players in the Global Duchenne Muscular Dystrophy Drugs Market are BioMarin Pharmaceutical, Eli Lilly, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics while other prominent vendors include Acceleron Pharma, Akashi Therapeutics, Asklepios BioPharmaceuticals, Bristol-Myers Squibb, Capricor Therapeutics, Catabasis Pharmaceuticals, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Marathon Pharmaceuticals, Nippon Shinyaku, Nobelpharma, Pfizer, Summit Therapeutics and Taiho Pharmaceutical

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For further information on this report, please visit -

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Duchenne Muscular Dystrophy - Pipeline Review, H1 2015
- Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2015
- Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
- EpiCast Report: Duchenne Muscular Dystrophy - Epidemiology Forecast to 2023
- PTC Therapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile